Navigation Links
New Natural Product from Zurich Pharmaceuticals Downs Appetite
Date:7/24/2008

BOSTON, July 24 /PRNewswire/ -- Health and nutrition researcher Frank Ervolino, ND, investigated a product that claims success in suppressing appetite without the risks associated with stimulants. He reports that Appetite Down (http://www.appetitedown.com), a natural product from Zurich Pharmaceuticals, makes novel use of an established ingredient with promising results.

Consumers will take drastic measures to lose weight. In fact, in the U.S., where the CDC estimates that greater than 30% of adults are obese, consumers spend up to $50 billion a year to combat fat. That includes an estimated $5 billion spent in weight loss and appetite suppression supplements and 200,000 bariatric -- or weight loss -- surgeries in 2007.

Nowhere are there more promises -- and questionable results -- than in the supplement market.

A "Who's Who" of health organizations caution against weight loss and appetite suppression products. Harvard Medical School, the Mayo Clinic, and Consumer Reports all have lists of ingredients that don't work or are potentially harmful.

Even when safe, there are factors that cause concern about appetite control products. Thermogenic ingredients, like caffeine, are powerful stimulants that can be highly addictive. And non-thermogenic remedies can require daily doses of as much as 3 grams to be effective.

Ervolino has watched patients grapple with a common enemy -- the urge to eat. Appetite Down is an all-natural appetite suppression lozenge that uses Gymnema sylvestre in a proprietary formulation to curb hunger cravings. It's also caffeine-free and ephedrine-free.

Gymnema has been used as a natural remedy for blood sugar regulation for centuries. A 2003 Harvard Medical School meta-analysis reviewed over 100 clinical trials involving over 4,500 patients with diabetes or impaired glucose tolerance. It concluded that Gymnema sylvestre was safe and demonstrated "positive preliminary results."

Ervolino was impressed by another feature of Gymnema sylvestre. Research indicates that delivering gymnemic acid in a slow-dissolving lozenge can block the sense of sweetness and discourage appetite for up to 2 hours. Appetite Down does this in a slow-release lozenge that uses high-impact sweeteners to mask Gymnema's natural bitterness.

Diet management and weight loss in the U.S. are urgent and serious matters. Ervolino's research suggests that stimulant-free, non-addictive natural products like Appetite Down may provide a useful aid in the battle against obesity.

Appetite Down is a new product, and has not yet been tested in a clinical setting, but its potential is promising, Ervolino concludes.


'/>"/>
SOURCE Zurich Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing
2. Fat Grafting Provides Permanent, Natural Looking Results - Dr. Michael Law Explains Fat Injections as a New Trend in Facial Plastic Surgery
3. Sweet Dreams, Sweet Breath: MedGen Inc. Retains TransMedia Group to Send Media a Wake-Up Call About an All-Natural, Quick New Way to Slumber Land
4. The Chopra Center for Wellbeing Introduces Ayurnas: A Soothing Natural Remedy for Sinus Congestion, Chronic Headaches, and Cold Symptoms
5. Breast Augmentation Raleigh Natural Looking Results with Saline or Silicone Implants
6. Children are naturally prone to be empathic and moral
7. Stay Safe This Summer With Chemical-Free Sunscreen and DEET-Free Bug Repellent, Says Natural Solutions Magazine
8. New Injectable Collagen Filler Offers Natural Results
9. Finding suggests novel ways to boost vaccination or natural defenses
10. Natural Remedies to Treat Animals Complex Emotions
11. Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme ... Center for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) ... has compiled into a single volume a compelling argument that the disease does exist ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to ... new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug rehab ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 28, 2017 ... Research and Markets has announced the ... 2025" report to their offering. The global ... of USD 239.8 billion by 2025. The rising prevalence of lifestyle-induced ... over the forecast period. Advancements in recombinant molecular technologies and high ...
(Date:2/28/2017)... , Feb. 28, 2017  Rigel Pharmaceuticals, Inc. ... it will report its fourth quarter and year ... March 7, 2017.  Rigel senior management will follow ... webcast at 5:00pm Eastern Time (2:00pm Pacific Time) ... can access the live conference call by dialing ...
(Date:2/28/2017)... SOUTH SAN FRANCISCO, Calif. , Feb. 27, ... company developing proprietary therapeutics for the treatment of ... drug delivery platform, today announced that the U.S. ... initial review of the ropinirole implant Investigational New ... hold the initiation of the clinical study pending ...
Breaking Medicine Technology: